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REVIEW OF HOME READINESS INSTRUMENTSTO ASSESS
RECOVERY POST-SURGERY
Asmussen M1,Wendicke K1, Heyes A2, Priaulx J2, Goad C2
1Nycomed, Roskilde, Denmark, 2Mapi Values, Macclesﬁeld, UK
OBJECTIVES: Minimising post-surgery length of stay is impor-
tant to patients, clinicians and payers who want to optimise
recovery rates and minimise costs. However, evaluating new
products and procedures using actual length of stay is inﬂuenced
by hospital payment incentives, organisational structures and
socio-economic factors. This study aimed to identify instruments
to measure post-anaesthesia home readiness and evaluate their
suitability for use in a clinical trial. METHODS: A literature
review was carried out to identify published evidence including
home readiness instruments. Medline, Embase and Biosis data-
bases were searched for RCTs and instrument-speciﬁc publica-
tions. The internet was searched for health technology
assessments, economic evaluations and guidelines. An inventory
of instruments was compiled and, for each, the suitability of use
in a clinical trial setting was assessed in terms of previous
examples of use in a clinical trial, evidence of validation and
reliability, compatibility with other recovery measures, support-
ing information and application to an in-patient setting.
RESULTS: Fifteen papers provided evidence of the use of the
Post-Anaesthetic Discharge Scoring System (PADS) [1] in a
variety of trial settings and validation work. Nine papers referred
to other instruments measuring home readiness but no other
instrument had been used in more than one trial or validated.
The British Association of Day Surgery referred to PADS in their
published guidelines. There was an example of PADS in an
economic evaluation of fast-tracking recovery [2]. CONCLU-
SIONS: PADS was found to be the most appropriate instrument
for assessing home readiness as it has undergone more validation
than other identiﬁed measures and there is evidence of its use
in multiple RCTs. [1] Chung et al. A post-anesthetic discharge
scoring system for home readiness after ambulatory surgery. J
Clin Anesth 1995;7:500–6; [2] Song et al. Fast-tracking (by-
passing the PACU) does not reduce nursing workload after
ambulatory surgery. Br J Anaesth 2004;93:768–4.
SYSTEMIC DISORDERS/CONDITIONS—
Patient-Reported Outcomes Studies
PSY42
E-DIARY COMPLIANCE IN ACUTE PAIN STUDIES
Marino B, Platko J, Raymond S
PHT Corporation, Boston, MA, USA
OBJECTIVES: In acute pain studies, subjects are asked to report
on symptoms at speciﬁc intervals after dosing. One or more
assessments are often primary endpoints. When timed assess-
ments are collected on paper the actual time the assessments
were completed is unknown, and enforcing completion of the
assessment at a speciﬁc time is impossible. Electronic patient
reported outcome technologies (ePRO) allow control over the
window in which a subject can complete the electronic diary
(e-Diary), and a time stamp associated with diary completion.
E-Diaries assure the investigator of more reliable information:
the 120 minute assessment was completed at or near 120
minutes. But is there a down side? With a restricted window of
time for completing an e-diary in the acute pain model, how
compliant will subjects be? METHODS: Diary completion was
examined in 12 randomized clinical trials using the acute pain
model. Indications were surgical pain, migraine, or break
through pain. Subjects completed pain diaries at timed intervals
after dosing. In 4 trials, subjects completed at least some of the
assessments in the clinic or post surgical area allowing com-
parison of compliance in supervised settings to compliance with
e-diaries at home. Frequency of the assessments varied across the
trials, allowing some description of factors which may inﬂuence
compliance. Finally, design features, like a reminder alarm, were
correlated with time of diary compliance to understand the
usefulness of these features. RESULTS: e-Diary compliance in
supervised setting can be as high as 100%. Compliance in unsu-
pervised settings is typically 80%, although frequent assessments
correspond with decreased compliance. In one study that re-
quired extensive frequent assessments, e-Diary compliance is
much lower. Indication does not correlate with e-Diary compli-
ance in unsupervised settings. CONCLUSIONS: Factors that
correspond with e-diary compliance are supervision, frequency
and overall demand on subjects.
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THE IMPACT OF ROMIPLOSTIM ON PATIENT-REPORTED
OUTCOMES MEASURED BYTHE EUROQOL (EQ-5D)
Sanz M1,Aledort L2, Danese M3, Guo M4, Isitt J4
1University Hospital La Fe,Valencia, Spain, 2Mount Sinai Hospital, New
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OBJECTIVES: The study objective was to estimate health status
changes using the EuroQol (EQ-5D) in immune thrombocy-
topenia purpura (ITP) patients treated with romiplostim in two,
24-week randomized placebo controlled phase 3 trials.
METHODS: The EQ-5D was scored from 0 to 1 for both the
summary score (Index) and the visual analog scale (VAS) and was
given at baseline and every four weeks thereafter. Patients
received either romiplostim (titrated to maintain platelets
between 50 to 200 ¥ 109/L) or placebo at a 2:1 ratio. One trial
was conducted in patients (n = 62) with ITP without splenectomy
and the other was among patients (n = 63) refractory to splenec-
tomy. We pooled data across studies and evaluated the EQ-5D
change from baseline to week 24. We compared romiplostim
with placebo, as well as responders with non-responders.
Responders had mean platelet counts 50 ¥ 109/L for 6 of the
last 8 weeks on the study (regardless of treatment group). Effects
were estimated using linear regression (ﬁnal score as the depen-
dent variable adjusting for baseline score). Responder analyses
incorporated age and gender as covariates. Missing follow up
data were imputed using the last available value, unless a subject
died, in which case zero was imputed. Patients with insufﬁcient
data were excluded (n = 11). RESULTS: At baseline the median
age was 52 years (range 21 to 88), 65% were females, 82% were
white, and the mean platelet count was 16.5 ¥ 109/L. The differ-
ences in mean change from baseline for romiplostim compared
to placebo was 0.06 for the Index (p = 0.017) and 0.05 for VAS
(p = 0.040). Adjusted mean changes were similar for responders
versus non-responders (0.06 and 0.10 for the Index and VAS,
p < 0.05). CONCLUSIONS: Romiplostim use was associated
with signiﬁcant improvement in health status. Furthermore, these
results will be useful for assessing the value of romplostim in
economic models.
PSY44
UNDERSTANDING AND ASSESSINGTHE IMPACT OF
PRESCRIPTION WEIGHT LOSS MEDICATION; CONCEPTUAL,
GENDER AND CULTURAL ISSUES
Brod M1, Hammer M2, Lessard S3, Kragh N2
1The BROD GROUP, Mill Valley, CA, USA, 2Novo Nordisk A/S,
Bagsværd, Denmark, 3The Brod Group, Mill Valley, CA, USA
OBJECTIVES: As obesity becomes a global epidemic, the use
of weight loss medications (WLM) continues to increase. The
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impact of WLM on functioning and well-being is not well under-
stood, cultural differences have been largely ignored and discrep-
ancies between clinician and patient perceptions have been
noted. The purpose of the study was to develop a measure of the
impact of WLM applicable for use in clinical trials and clinical
practice. METHODS: Qualitative data were collected from the
literature, patients (n = 82) and experts (n = 9) in three countries
(US, France, UK) were interviewed regarding the impact of WLM
on functioning, well-being and health. Interview transcripts were
thematically coded. Based on these data, a conceptual model of
the impact of WLM on functioning, well-being and symptom
experience was developed and a patient reported outcomes
(PRO) measure generated. RESULTS: The impact of WLM on
psychological health, interference in daily life, treatment burden,
efﬁcacy and side effects was considered signiﬁcant by patients.
Key modiﬁers to this impact (i.e., age, occupation, stress) and
consequences (i.e., compliance, reduced productivity) were
noted. Based on a conceptual model, a WLM treatment related
impact measure (TRIM-Weight) was generated with ﬁve discrete
domains. Discrepancies between perceived patient and clinician
impacts were identiﬁed, most notably for the impact on sleep and
daily life as well as perceived importance of side effects. Gender
and cultural differences were also identiﬁed. For example, men
tended to be more goal-oriented in their weight loss goals than
women and side effect proﬁles differed by country as a result of
prescription patterns. CONCLUSIONS: A measure of the impact
of WLM on functioning, well-being and health was developed.
The instrument development process, full conceptual model, and
cultural, gender and clinician/patient differences will be pre-
sented. This information should help clinicians to identify key
PRO issues for WLM, facilitate targeted treatments and allow for
meaningful measurement of treatment effect.
PSY45
PATIENT ACCEPTABLE SYMPTOM STATE (PASS) IN
EUROPEAN PATIENTS WITH MODERATE-SEVERE
PLAQUE PSORIASIS
Molta CT, Boggs R, Singh A,Yang S
Wyeth Pharmaceuticals, Inc, Collegeville, PA, USA
OBJECTIVES: To determine a Patient Acceptable Symptom State
(PASS) for European patients with moderate-severe plaque pso-
riasis, and to compare Psoriasis Activity and Severity Index
(PASI) improvement for patients attaining this state to the
current clinical trial benchmark of 75% PASI improvement from
baseline. METHODS: Patients with Psoriasis Area and Severity
Index (PASI) > 10 were randomized 1:1 to Enbrel 25 mg BIW or
Enbrel 50 mg BIW for twelve weeks as the ﬁrst stage of a
54-week trial. PASI scores can range from 0 to 72, with higher
scores indicating more severe disease and scores > 10 indicating
moderate-severe disease. Patients on the higher dose were tem-
porarily removed from treatment if their Physician Global
Assessment score determined their skin disease had become mild,
almost clear or clear. PASI was assessed at baseline and at week
12. Patients completed a satisfaction questionnaire at week 12.
Patients reporting that they were ‘very satisﬁed’ or ‘satisﬁed’
were counted as satisﬁed; all others—including those who
reported that they were ‘somewhat satisﬁed’—were counted as
not satisﬁed. The PASS method for determining a symptom state
that patients ﬁnd acceptable was developed for osteoarthritis by
Turbach, Ravaud, Baron, et al. (Annals of the Rheumatic Dis-
eases, 2005) among other authors and other diseases. Following
the Turbach et al method, a cumulative percentage of satisﬁed
patients as well as a cumulative percentage of patients who were
not satisﬁed was plotted vs. week-12 PASI. The week-12 PASI
score with the greatest separation between the two cumulative
curves was judged to be an acceptable state. The PASI improve-
ment from baseline for patients with week-12 PASI scores closest
to this state were obtained and a mean PASI improvement for
them was calculated. Patients were pooled across treatment arms
for these analyses. RESULTS: Baseline mean PASI was 22.32 for
the 711 patients. At week 12, mean PASI was 8.70, representing
a 61% PASI improvement from baseline. PASS was determined
to be a week-12 PASI of 6.9, with 66.2% of satisﬁed patients
having a week-12 PASI below (better than) 6.9 compared to
25.6% of not-satisﬁed patients. A sensitivity analysis counting
only ‘very satisﬁed’ patients as satisﬁed also determined PASS at
week 12 to be a PASI of 6.9. A week-12 PASI interval of 6.6 to
7.2 and centered on 6.9 included 32 patients, for whom the mean
PASI improvement from baseline was 62.5% with a 95% conﬁ-
dence interval of 58.2% to 66.9%. This percent improvement is
less than the 75% PASI improvement from baseline threshold
commonly used as a primary endpoint in clinical trials. CON-
CLUSIONS: These 711 moderate-severe psoriasis patients had a
Patient Acceptable Symptom State (PASS) worse than the 75%
PASI improvement commonly used as a primary endpoint in
clinical trials. Further research is needed on ways to explicitly
incorporate patient preference in estimates of clinical response.
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PATIENT-REPORTED OUTCOMES (PRO) AND ECONOMICS OF
MIGRAINE IN GERMANY
Breitscheidel L1, Kreyenberg K1, Stridde E2, Eichmann F1
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OBJECTIVES: To assess PRO and costs in German patients with
migraine, speciﬁcally for guideline-, non-guideline- and self-
treatment-groups. METHODS: Patients (n = 117), consecutively
recruited by physicians in general practice (n = 50) in 2005, were
categorized into the three groups (n = 65 self-treatment, n = 32
guideline-, n = 20 non-guideline-groups). PRO were assessed
by von Korff Index, SF-36, and Patient Health Questionnaire
Depression (PHQ-D) questionnaires at time of enrollment. Data
on resource utilization due to migraine was collected retrospec-
tively for 6 months. Groups were compared using multivariable
general linear modeling (GLM). RESULTS: Average duration of
migraine was about 14.1 (SD 11.8) years and was comparable
among the groups. Patients with self-treatment were younger
than patients in guideline- or non-guideline-group (40.5 vs. 47.3
vs. 45.1 years, mean age, p = 0.0224). The groups did not differ
in other socio-demographic characteristics. Mean SF-36 scores
in our study population were worse compared to the general
population in Germany (mean physical and mental component
scores 43.0  8.6, 42.0  11.9). However, groups were compa-
rable regarding SF-36, von Korff Index and PHQ-D items. Mean
total costs per patient and 6-month period were €527.50
[95%CI 251.93; 803.07] vs. €979.37 [95%CI 577.62; 1381.11]
vs. €1281.30 [95%CI 124.64; 2437.97] (self-treatment-vs.
guideline-vs. non-guideline-group, respectively, p = 0.2739, by
GLM, adjusted by age). The major cost factors in the self-
treatment group were reduction of earning capacity, remedies,
and sport activities (44.4%, 18.7%, and 15.8% of the mean
total cost per patient, respectively) while in guideline-group the
major cost factors were prescribed medications, reduction in
earning capacity, and visits to physicians (43.0%, 14.5%, and
14.3%, respectively). The major cost factors in non-guideline
and guideline-groups were similar. CONCLUSIONS: PRO in
patients with migraine are worse compared to the general refer-
ence population in Germany. Societal mean total costs and
PRO are comparable among guideline-, non-guideline- and
self-treatment-groups.
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